{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:40Z","timestamp":1794360520020,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormone receptor-positive\/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.<\/jats:p>","DOI":"10.1038\/s41523-026-00904-5","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:54:25Z","timestamp":1769633665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dynamic biomarkers in hormone receptor-positive\/HER2-negative breast cancer trials: a new hope for precision oncology"],"prefix":"10.1038","volume":"12","author":[{"given":"Giuseppe","family":"Di Grazia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"S\u00e1nchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Climent","family":"Casals-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","unstructured":"Soragni, A. et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-025-00824-9 (2025).","DOI":"10.1038\/s41568-025-00824-9"},{"key":"904_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53849-3","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Multi-omics with dynamic network biomarker algorithm prefigures organ-specific metastasis of lung adenocarcinoma. Nat. Commun. 15, 9855 (2024).","journal-title":"Nat. Commun"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrd.2016.233","volume":"16","author":"WJ Lesterhuis","year":"2017","unstructured":"Lesterhuis, W. J. et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat. Rev. Drug Discov. 16, 264\u2013272 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"904_CR4","doi-asserted-by":"crossref","unstructured":"Kreipe, H., Harbeck, N. & Christgen, M. Clinical validity and clinical utility of Ki67 in early breast cancer. Ther. Adv. Med. Oncol. 14, 17588359221122725 (2022).","DOI":"10.1177\/17588359221122725"},{"key":"904_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2020.38.15_suppl.504","volume":"38","author":"CX Ma","year":"2020","unstructured":"Ma, C. X. et al. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER\u2009+\u2009HER2- BC) in postmenopausal (PM) women: Alliance A011106. J. Clin. Oncol. 38, 504\u2013A011504 (2020).","journal-title":"J. Clin. Oncol."},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","volume":"40","author":"UA Nitz","year":"2022","unstructured":"Nitz, U. A. et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR\u2009+\u2009\/HER2\u2013 early breast cancer. J. Clin. Oncol. 40, 2557\u20132567 (2022).","journal-title":"J. Clin. Oncol."},{"key":"904_CR8","doi-asserted-by":"crossref","unstructured":"Harbeck, N. et al. ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR\u2009+\u2009\/HER2- early breast cancer (EBC). J. Clin. Oncol. 38, TPS601\u2013TPS601 (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS601"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"104743","DOI":"10.1016\/j.esmoop.2025.104743","volume":"10","author":"N Harbeck","year":"2025","unstructured":"Harbeck, N. et al. 189\u2009O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR\u2009+\u2009\/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle-trial. ESMO Open 10, 104743 (2025).","journal-title":"ESMO Open"},{"key":"904_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 21, 33\u201343 (2020).","journal-title":"Lancet Oncol."},{"key":"904_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0129-6","volume":"8","author":"B Wallden","year":"2015","unstructured":"Wallden, B. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genom. 8, 54 (2015).","journal-title":"BMC Med. Genom."},{"key":"904_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00451-9","volume":"8","author":"F Schettini","year":"2022","unstructured":"Schettini, F., Bras\u00f3-Maristany, F., Kuderer, N. M. & Prat, A. A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. NPJ Breast Cancer 8, 85 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"904_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual, T. et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer 10, 20 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccell.2025.01.002","volume":"43","author":"C Denkert","year":"2025","unstructured":"Denkert, C. et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer\u2014from intrinsic to adaptive subtyping. Cancer Cell 43, 232\u2013247.e4 (2025).","journal-title":"Cancer Cell"},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"103989","DOI":"10.1016\/j.esmoop.2024.103989","volume":"9","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-negative breast cancer: the NEOENDO translational study. ESMO Open 9, 103989 (2024).","journal-title":"ESMO Open"},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"103619","DOI":"10.1016\/j.esmoop.2024.103619","volume":"9","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-low and HER2-0 breast cancer. ESMO Open 9, 103619 (2024).","journal-title":"ESMO Open"},{"key":"904_CR17","doi-asserted-by":"publisher","first-page":"103900","DOI":"10.1016\/j.critrevonc.2022.103900","volume":"181","author":"M Sirico","year":"2023","unstructured":"Sirico, M. et al. Neoadjuvant endocrine therapy for luminal breast tumors: state of the art, challenges and future perspectives. Crit. Rev. Oncol. Hematol. 181, 103900 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"904_CR18","doi-asserted-by":"crossref","unstructured":"Garcia-Fructuoso I, et al. Abstract PS2-07: Intrinsic Subtype at Progression to CDK4\/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive\/HER2-Negative Metastatic Breast Cancer (MBC). Clin. Cancer Res. 31, PS2\u201307 (2025).","DOI":"10.1158\/1557-3265.SABCS24-PS2-07"},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"105823","DOI":"10.1016\/j.ebiom.2025.105823","volume":"118","author":"MB Sirv\u00e9n","year":"2025","unstructured":"Sirv\u00e9n, M. B. et al. Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER\u2009+\u2009\/HER2+ early breast cancer: a POETIC translational study. EBioMedicine 118, 105823 (2025).","journal-title":"EBioMedicine"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2017.07.041","volume":"84","author":"CM Focke","year":"2017","unstructured":"Focke, C. M. et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur. J. Cancer 84, 219\u2013227 (2017).","journal-title":"Eur. J. Cancer"},{"key":"904_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4132\/jptm.2015.12.24","volume":"50","author":"YR Chung","year":"2016","unstructured":"Chung, Y. R., Jang, M. H., Park, S. Y., Gong, G. & Jung, W.-H. Interobserver variability of Ki-67 measurement in breast cancer. J. Pathol. Transl. Med. 50, 129\u2013137 (2016).","journal-title":"J. Pathol. Transl. Med."},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/j.annonc.2023.09.564","volume":"34","author":"T Pascual","year":"2023","unstructured":"Pascual, T. et al. 387MO First results of the SOLTI-1903 HOPE\u2019s patient-centric molecular screening program in advanced breast cancer. Ann. Oncol. 34, S341\u2013S342 (2023).","journal-title":"Ann. Oncol."},{"key":"904_CR23","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.jlb.2025.100299","volume":"8","author":"S Malik","year":"2025","unstructured":"Malik, S. & Zaheer, S. The impact of liquid biopsy in breast cancer: redefining the landscape of non-invasive precision oncology. J. Liq. Biopsy 8, 100299 (2025).","journal-title":"J. Liq. Biopsy"},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/cancers12061632","volume":"12","author":"A Genna","year":"2020","unstructured":"Genna, A. et al. EMT-associated heterogeneity in circulating tumor cells: sticky friends on the road to metastasis. Cancers 12, 1632 (2020).","journal-title":"Cancers"},{"key":"904_CR25","doi-asserted-by":"publisher","first-page":"100117","DOI":"10.1016\/j.jlb.2023.100117","volume":"2","author":"E Nicol\u00f2","year":"2023","unstructured":"Nicol\u00f2, E. et al. Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: methods of detection and clinical implications. J. Liq. Biopsy 2, 100117 (2023).","journal-title":"J. Liq. Biopsy"},{"key":"904_CR26","doi-asserted-by":"crossref","unstructured":"Rack, B. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl Cancer Inst. 106, dju066 (2014).","DOI":"10.1093\/jnci\/dju066"},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct. Target Ther. 9, 336 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"904_CR28","doi-asserted-by":"publisher","unstructured":"Mittendorf, E. A. et al. Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03725-4 (2025).","DOI":"10.1038\/s41591-025-03725-4"},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua, M. J. M. et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann. Oncol. 32, 229\u2013239 (2021).","journal-title":"Ann. Oncol."},{"key":"904_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua, M. J. M. et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41, 1091\u20131102.e4 (2023).","journal-title":"Cancer Cell"},{"key":"904_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann. Oncol. 34, 200\u2013211 (2023).","journal-title":"Ann. Oncol."},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"TPS620","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS620","volume":"42","author":"K Pfister","year":"2024","unstructured":"Pfister, K. et al. The SURVIVE study: liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer. J. Clin. Oncol. 42, TPS620\u2013TPS620 (2024).","journal-title":"J. Clin. Oncol."},{"key":"904_CR33","doi-asserted-by":"crossref","unstructured":"Ignatiadis, M. et al. EORTC-2129-BCG: Elacestrant for treating ER\u2009+\u2009\/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). J. Clin. Oncol. 43, (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS620"},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781\u2013791 (2004).","journal-title":"N. Engl. J. Med."},{"key":"904_CR35","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage, J. B. et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 32, 3483\u2013S3489 (2014).","journal-title":"J. Clin. Oncol."},{"key":"904_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov."},{"key":"904_CR37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 23, 1367\u20131377 (2022).","journal-title":"Lancet Oncol."},{"key":"904_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M. & Schiff, R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573\u2013583 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"904_CR39","doi-asserted-by":"publisher","unstructured":"Bidard, F.-C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2502929 (2025).","DOI":"10.1056\/NEJMoa2502929"},{"key":"904_CR40","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis, M. J. et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor\u2013rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2014ACOSOG Z1031. J. Clin. Oncol. 29, 2342\u2013Z2349 (2011).","journal-title":"J. Clin. Oncol."},{"key":"904_CR41","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22, 858\u2013871 (2021).","journal-title":"Lancet Oncol."},{"key":"904_CR42","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403, 1649\u20131659 (2024).","journal-title":"Lancet"},{"key":"904_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00331-8","volume":"7","author":"A Gombos","year":"2021","unstructured":"Gombos, A. et al. FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ Breast Cancer 7, 1\u20139 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"904_CR44","doi-asserted-by":"publisher","first-page":"e2423435","DOI":"10.1001\/jamanetworkopen.2024.23435","volume":"7","author":"GA Ulaner","year":"2024","unstructured":"Ulaner, G. A. et al. ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer. JAMA Netw. Open 7, e2423435 (2024).","journal-title":"JAMA Netw. Open"},{"key":"904_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.annonc.2024.02.007","volume":"35","author":"A Gennari","year":"2024","unstructured":"Gennari, A. et al. Early prediction of endocrine responsiveness in ER\u2009+\u2009\/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT\/PET. Ann. Oncol. 35, 549\u2013558 (2024).","journal-title":"Ann. Oncol."},{"key":"904_CR46","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 4.2025. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/ https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (2025)."},{"key":"904_CR47","doi-asserted-by":"publisher","unstructured":"European Association of Nuclear Medicine (EANM) Focus meeting 6 consensus on molecular imaging in breast cancer. EANM J 100004 https:\/\/doi.org\/10.1016\/J.EANMJ.2025.100004 (2025).","DOI":"10.1016\/J.EANMJ.2025.100004"},{"key":"904_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang, H. & Yee, D. I-SPY 2: a Neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr. Breast Cancer Rep. 11, 303\u2013310 (2019).","journal-title":"Curr. Breast Cancer Rep."},{"key":"904_CR49","doi-asserted-by":"publisher","first-page":"PD11-04","DOI":"10.1158\/1538-7445.SABCS22-PD11-04","volume":"83","author":"T Pascual","year":"2023","unstructured":"Pascual, T. et al. Abstract PD11-04: PD11-04 primary results of SOLTI-1503 PROMETEO phase 2 trial of combination of talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. Cancer Res. 83, PD11-04\u2013PD11-04 (2023).","journal-title":"Cancer Res."},{"key":"904_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00710-x","volume":"10","author":"S Pernas","year":"2024","unstructured":"Pernas, S. et al. Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer 10, 101 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"904_CR51","doi-asserted-by":"publisher","first-page":"102816","DOI":"10.1016\/j.ctrv.2024.102816","volume":"130","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. Navigating the complex relationship between human gut microbiota and breast cancer: physiopathological, prognostic and therapeutic implications. Cancer Treat. Rev. 130, 102816 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"904_CR52","doi-asserted-by":"crossref","unstructured":"Guan, X. et al. Gut Microbiota profiling in patients with HER2-negative metastatic breast cancer receiving metronomic chemotherapy of capecitabine compared to those under conventional dosage. Front. Oncol. 10, 902 (2020).","DOI":"10.3389\/fonc.2020.00902"},{"key":"904_CR53","doi-asserted-by":"publisher","first-page":"112948","DOI":"10.1016\/j.ejca.2023.112948","volume":"191","author":"F Schettini","year":"2023","unstructured":"Schettini, F. et al. Faecal microbiota composition is related to response to CDK4\/6-inhibitors in metastatic breast cancer: a prospective cross-sectional exploratory study. Eur. J. Cancer 191, 112948 (2023).","journal-title":"Eur. J. Cancer"},{"key":"904_CR54","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1016\/j.annonc.2023.09.446","volume":"34","author":"F Ligorio","year":"2023","unstructured":"Ligorio, F. et al. 248\u2009P Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus\/minus metformin: The BREAKFAST trial. Ann. Oncol. 34, S282\u2013S283 (2023).","journal-title":"Ann. Oncol."},{"key":"904_CR55","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1016\/j.annonc.2023.09.2829","volume":"34","author":"C Vernieri","year":"2023","unstructured":"Vernieri, C. et al. 352TiP Neoadjuvant chemo-immunotherapy plus\/minus fasting-like approach in stage II-III triple-negative breast cancer patients: the phase II randomized BREAKFAST-2 trial. Ann. Oncol. 34, S322\u2013S323 (2023).","journal-title":"Ann. Oncol."},{"key":"904_CR56","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1093\/oncolo\/oyad060","volume":"28","author":"G Vernaci","year":"2023","unstructured":"Vernaci, G. et al. Characterization of gut microbiome composition in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy. Oncologist 28, e703\u2013e711 (2023).","journal-title":"Oncologist"},{"key":"904_CR57","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973\u2013980 (2020).","journal-title":"Science"},{"key":"904_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2025.03.005","volume":"36","author":"G Antonarelli","year":"2025","unstructured":"Antonarelli, G. et al. Redefining clinical trial strategic design to support drug approval in medical oncology. Ann. Oncol. 36, 645\u2013650 (2025).","journal-title":"Ann. Oncol."},{"key":"904_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-024-01106-8","volume":"7","author":"C McGenity","year":"2024","unstructured":"McGenity, C. et al. Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy. NPJ Digit. Med. 7, 1\u201319 (2024).","journal-title":"NPJ Digit. Med."},{"key":"904_CR60","doi-asserted-by":"publisher","unstructured":"Bidard, F.-C. et al. Identifying patients with low relapse rate despite high-risk estrogen receptor\u2013positive\/human epidermal growth factor receptor 2-negative early breast cancer: development and validation of a clinicopathologic assay. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-00742 (2025).","DOI":"10.1200\/JCO-25-00742"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00904-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:05:06Z","timestamp":1772543106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00904-5","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R. S\u00e1nchez Bayona reports advisory\/consulting\/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, Eisai, GlaxoSmithKline, Reveal Genomics, and Gilead, travel expenses from Pfizer, AstraZeneca, Gilead, Novartis, and Roche. D. Generali reports Advisory role for Roche, Novartis, Pfizer; speaker honoraria from Roche, Lilly, Novartis, Pfizer, Menarini, AstraZeneca, Gilead; travel Grants from Roche; research funding (to the Uni) from Novartis. T. Pascual reports advisory and consulting fees or speaker honoraria from Novartis, Astra Zeneca, Lilly, Pfizer, Veracyte, Gilead, and Roche, and support for attending meetings and\/or travel from Gilead. A. Gennari reports Research grants: Pharmanutra, AAA; advisory boards, activities as a speaker, travel grants, consultancy: Roche, Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, AstraZeneca, MSD, Seagen, Gilead, Pierre Fabre, Eisai, Exact Sciences, Stemline. J. Cort\u00e9s reports ARIAD Grant\/Contract; AstraZeneca Grant\/Contract, Other, Consulting; Baxalta GMBH\/Servier Affaires Grant\/Contract; Bayer Grant\/Contract; Eisai Grant\/ Contract, Travel, Other, honoraria; Guardant Health Grant\/Contract; MSD Grant\/Contract, Other, honoraria, consulting; Pfizer Grant\/Contract, Travel, Other, honoraria, consulting; Puma Grant\/Contract; Roche Grant\/Contract, Travel, Other, honoraria, consulting; Piqur Grant\/Contract; Novartis Travel, Other, honoraria; Celgene Other, consulting, honoraria; Samsung Other, honoraria; Daiichi Sankyo Travel, Other, honoraria, consulting; Eli Lilly Other, honoraria; Reveal Genomics Other, Consulting; Seagen Other, Consulting; Menarini Other, Consulting; Leuko Stock, Other, Consulting. N. Harbeck reports consulting fees from Gilead, Sandoz and Seagen; speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Seagen; honoraria for data safety monitoring board from Roche; and a leadership position at the West German Study Group (minority ownership). A. Prat reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT\/EP2016\/080056, PCT\/EP2022\/ 086493, PCT\/EP2023\/060810, EP23382703, and EP23383369; editor of NPJ Breast Cancer journal. F. Schettini reports honoraria from Novartis, Gilead, Veracyte, Astra-Zeneca and Daiichy-Sankyo for educational events\/materials, advisory fees from Pfizer, Astra-Zeneca, Daiichy-Sankyo and Veracyte, and travel expenses from Novartis, Astra-Zeneca, Gilead and Daiichy-Sankyo. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}